{
  "id": "5a75df9483b0d9ea66000001",
  "type": "summary",
  "question": "What is the mechanism of action of Tisagenlecleucel?",
  "ideal_answer": "Tisagenlecleucel CD19-directed chimeric antigen receptor T cells (CART19) product that cause reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing cells. Its is is approved for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29039115",
    "http://www.ncbi.nlm.nih.gov/pubmed/28887358",
    "http://www.ncbi.nlm.nih.gov/pubmed/28751490",
    "http://www.ncbi.nlm.nih.gov/pubmed/28935694",
    "http://www.ncbi.nlm.nih.gov/pubmed/29058636",
    "http://www.ncbi.nlm.nih.gov/pubmed/29143249"
  ],
  "snippets": [
    {
      "text": "An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28935694",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887358",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058636",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH\u2122 (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29039115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Indeed, on August 30, 2017, the University of Pennsylvania-designed CD19-directed CART (CART-19) cell therapy (CTL019, tisagenlecleucel-t, Kymriah - Novartis) became the first CART therapy approved by the Food and Drug Administration (FDA) for acute lymphoblastic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143249",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tisagenlecleucel (CTL019) is an investigational immunotherapy that involves reprogramming a patient's own T cells with a transgene encoding a chimeric antigen receptor to identify and eliminate CD19-expressing cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28935694",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058636",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CTL019, or KYMRIAH\u2122 (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29039115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "an expert panel recommended approval of novartis s experimental chimeric antigen t cell therapy tisagenlecleucel for children and young adults with relapsed or refractory b cell acute lymphoblastic leukemia the therapy would be the first of its kind approved for cancer and has the potential to transform standard of care for advanced blood cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "novel immunotherapeutic agents targeting tumor site microenvironment are revolutionizing cancer therapy chimeric antigen receptor car engineered t cells are widely studied for cancer immunotherapy cd19 specific car t cells tisagenlecleucel have been recently approved for clinical application ongoing clinical trials are testing car designs directed at novel targets involved in hematological and solid malignancies in addition to trials of single target car t cells simultaneous and sequential car t cells are being studied for clinical applications multi target car engineered t cells are also entering clinical trials t cell receptor engineered car t and universal car t cells represent new frontiers in car t cell development in this study we analyzed the characteristics of car constructs and registered clinical trials of car t cells in china and provided a quick glimpse of the landscape of car t studies in china.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29058636",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "in this review we discuss the most recent developments in gene editing technology and discuss their application to adoptive t cell immunotherapy engineered t cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations most impressively cd19 directed chimeric antigen receptor t cells cart19 have led to impressive responses in patients with b cell leukemia and lymphoma ctl019 or kymriah tisagenlecleucel a cd19 car t cell product developed by novartis and the university of pennsylvania was recently approved for clinical use by the food and drug administration representing a landmark in the application of adoptive t cell therapies as cart19 enters routine clinical use improving the efficacy of this exciting platform is the next step in broader application novel gene editing technologies like crispr cas9 allow facile editing of specific genes within the genome generating a powerful platform to further optimize the activity of engineered t cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29039115",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "autologous patient specific chimeric antigen receptor t cell cart therapy has emerged as a powerful and potentially curative therapy for cancer especially for cd19 positive hematological malignancies indeed on august 30 2017 the university of pennsylvania designed cd19 directed cart cart 19 cell therapy ctl019 tisagenlecleucel t kymriah novartis became the first cart therapy approved by the food and drug administration fda for acute lymphoblastic leukemia however the development of cart technology and its wider application is partly limited by the patient specific nature of such a platform and by the time required for manufacturing the efficacious generation of universal allogeneic cart cells would overcome these limitations and represent a major advance in the field however several obstacles in the generation of universal cart cells need to be overcome namely the risk of cart rejection and the risk of graft versus host disease mediated by the allogeneic cart in this review we discuss the different strategies being employed to generate universal cart and provide our perspective on the successful development of a truly off the shelf cart product.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29143249",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}